Noridza Rivera-Rodriguez1, Fernando Cabanillas. 1. aAuxilio Cancer Center bUniversity of Puerto Rico, School of Medicine, San Juan, Puerto Rico cUniversity of Texas, M. D. Anderson Cancer Center, Houston, Texas dUniversity of South Florida, Moffitt Cancer Center Tampa, Florida, USA.
Abstract
PURPOSE OF REVIEW: This review will discuss the most recent literature regarding frontline therapy, treatment of patients not eligible for intensive chemotherapy, and novel agents for relapsed/refractory patients with mantle cell lymphoma (MCL). RECENT FINDINGS: Longer follow-up of previously studied intensive regimens still demonstrates encouraging results, but late relapses are still evident. Consolidation and maintenance strategies continue to be attractive options to be explored in this disease that is characterized by frequent relapses and short remissions. The combination of bendamustine-rituximab was demonstrated to be noninferior and less toxic to R-CHOP and should be considered the new standard of care for elderly patients. Multiple novel agents directed towards different molecular targets like BTK, mTOR, PI3K, HDAC, and BCL-2, involved in the pathogenesis of MCL have shown promising results. SUMMARY: Management of MCL still represents a challenge due to heterogeneity of the disease. As we approach the molecular era of oncology, future strategies should focus on combination of newer agents with known effective regimens to improve outcome.
PURPOSE OF REVIEW: This review will discuss the most recent literature regarding frontline therapy, treatment of patients not eligible for intensive chemotherapy, and novel agents for relapsed/refractory patients with mantle cell lymphoma (MCL). RECENT FINDINGS: Longer follow-up of previously studied intensive regimens still demonstrates encouraging results, but late relapses are still evident. Consolidation and maintenance strategies continue to be attractive options to be explored in this disease that is characterized by frequent relapses and short remissions. The combination of bendamustine-rituximab was demonstrated to be noninferior and less toxic to R-CHOP and should be considered the new standard of care for elderly patients. Multiple novel agents directed towards different molecular targets like BTK, mTOR, PI3K, HDAC, and BCL-2, involved in the pathogenesis of MCL have shown promising results. SUMMARY: Management of MCL still represents a challenge due to heterogeneity of the disease. As we approach the molecular era of oncology, future strategies should focus on combination of newer agents with known effective regimens to improve outcome.
Authors: James N Kochenderfer; Mark E Dudley; Sadik H Kassim; Robert P T Somerville; Robert O Carpenter; Maryalice Stetler-Stevenson; James C Yang; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; Mark Raffeld; Steven Feldman; Lily Lu; Yong F Li; Lien T Ngo; Andre Goy; Tatyana Feldman; David E Spaner; Michael L Wang; Clara C Chen; Sarah M Kranick; Avindra Nath; Debbie-Ann N Nathan; Kathleen E Morton; Mary Ann Toomey; Steven A Rosenberg Journal: J Clin Oncol Date: 2014-08-25 Impact factor: 44.544
Authors: Frederick R Appelbaum; Claudio Anasetti; Joseph H Antin; Harold Atkins; Stella Davies; Steven Devine; Sergio Giralt; Helen Heslop; Ginna Laport; Stephanie J Lee; Brent Logan; Marcelo Pasquini; Michael Pulsipher; Edward Stadtmauer; John R Wingard; Mary M Horowitz Journal: Biol Blood Marrow Transplant Date: 2014-10-15 Impact factor: 5.742
Authors: Jennifer E Vaughn; Mohamed L Sorror; Barry E Storer; Thomas R Chauncey; Michael A Pulsipher; Richard T Maziarz; Michael B Maris; Parameswaran Hari; Ginna G Laport; Georg N Franke; Edward D Agura; Amelia A Langston; Andrew R Rezvani; Rainer Storb; Brenda M Sandmaier; David G Maloney Journal: Cancer Date: 2015-07-24 Impact factor: 6.860